Education:
2000-2005, B.S. in Clinical Medicine, West China Medical Center, Sichuan University, Sichuan, China
2005-2010, Ph.D. in Immunology, Peking Union Medical College, Beijing, China
Professional Positions:
2010-2014, Research Fellow, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, United States
2014-2017, Research Associate, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, United States
2017-2023, Assistant Professor, School of Medicine, Tsinghua University, Beijing, China
2023- 2024, Associate Professor, School of Medicine, Tsinghua University, Beijing, China
2024-present, Tenured Associate Professor, School of Medicine, Tsinghua University, Beijing, China
Research Areas:
T lymphocytes play a central role in anti-infection and anti-tumor responses. Abnormal T cells are also key pathogenic factors in autoimmune and inflammatory diseases. T cells are crucial in immunotherapy, with emerging therapies such as PD-1 antagonists and CAR-T cells involving interventions and modifications of T cells. Our laboratory has long been studying fundamental biological questions regarding T cells, including key regulatory processes and factors involved in activation, proliferation, differentiation, and memory, encompassing epigenetic, transcriptional, and metabolic factors. Based on this foundational research, we are actively developing various novel therapies based on T cells. Recently, our laboratory has induced a novel T cell state, termed "Immortal-like and Functional T cells" (TIF), which possesses nearly unlimited self-renewal capabilities similar to iPSCs while fully retaining the physiological functions of T cells. This represents a new form of mammalian cell existence, addressing the critical issue of the insufficient persistence of therapeutic T cells in vivo. In addition to their outstanding performance in tumor treatment, TIF-based T cells also have potential curative effects on various common non-tumor chronic diseases, such as asthma and rheumatoid arthritis. The Peng Min Laboratory will further explore the potential of T cell-based immunotherapies for common diseases and develop entirely new technological platforms to significantly reduce the cost of cell therapies, ultimately aiming to achieve complete cures for various common diseases, marking a breakthrough in medical history.
Honors and Awards:
2019 Outstanding Young Scholar Award, Qiu-Shi Science & Technologies Foundation
2018 Bayer Scholar
2015 Postdoctoral Researcher Award, Memorial Sloan Kettering Cancer Center
Selected Publications:
1.Gang Jin#, Yanyan Liu#, Lixia Wang, Zihao He, Xiaocui Zhao, Yuying Ma, Yuting Jia, Zhuoyang Li, Na Yin, Min Peng* . A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice. Nat Immunol. 2024. 2024. Jun;25(6):1059-1072.
Previewed by Nicholas Restifo and Luca Gattinoni in J Exp Med, “Synthetic soldiers: Turning T cells into immortal warriors”.
Highlighted by Yvonne Bordon in Nat Rev Immunol and Nat Rev Drug Discov, “CAR T cells take to the airways”.
2.Qing Shang,Zhuoyang Li, Na Yin, Min Peng*. Reconciling host-microbiota metabolic incompatibility safeguards male fertility. hlife. 2024;2:284–295
3.Lixia Wang#, Gang Jin#,Qiuping Zhou#, Yanyan Liu, Xiaocui Zhao, Zhuoyang Li, Na Yin, Min Peng*. Induction of immortal-like and functional CAR T cells by defined factors. J Exp Med. 2024 May 6;221(5):e20232368.
Previewed by Nicholas Restifo and Luca Gattinoni in J Exp Med, “Synthetic soldiers: Turning T cells into immortal warriors”.
4.Ying Liu#, Yuying Ma#, Jing Xu#, Guangyue Zhang#, Xiaocui Zhao#, Zihao He, Lixia Wang, Na Yin, Min Peng*. VMP1 prevents Ca2+ overload in endoplasmic reticulum and maintains naive T cell survival. J Exp Med. 2023 Jun 5;220(6):e20221068.
5.Min Peng*, Ming O. Li*. Metabolism along the life journey of T cells. Life Metabolism. 2023, 002(001)
6.Na Yin#, Gang Jin#, Yuying Ma, Hanfei Zhao, Guangyue Zhang, Ming O. Li, Min Peng*. SZT2 maintains hematopoietic stem cell homeostasis via nutrient-mediated mTORC1 regulation. J Clin Invest., 2022 Oct 17, 130(20):e146272.
7.Hanfei Zhao, Ying Liu, Lixia Wang, Gang Jin, Xiaocui Zhao, Jing Xu, Guangyue Zhang, Yuying Ma, Na Yin, Min Peng*. Genome-wide fitness gene identification reveals Roquin as a potent suppressor of CD8 T cell expansion and anti-tumor immunity. Cell Reports. 2021 Dec 7;37(10):110083.
8.Ke Xu#, Na Yin#, Min Peng, Efstathios G Stamatiades, Sagar Chhangawala, Amy Shyu, Peng Li, Xian Zhang, Mytrang H Do, Kristelle J Capistrano, Chun Chou, Christina S Leslie, Ming O Li. Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support effector T helper 17 cell responses. Immunity. 2021. 54(5):976-87.
9.Ke Xu, Na Yin, Min Peng, Efstathios G Stamatiades, Amy Shyu, Peng Li, Xian Zhang, Mytrang H Do, Zhaoquan Wang, Kristelle J Capistrano, Chun Chou, Andrew G Levine, Alexander Y Rudensky, Ming O Li. Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity. Science. 2021. Jan 22;371(6527):405-10.
10.Mytrang H. Do, Xinxin Wang, Xian Zhang, Chun Chou, Briana G. Nixon, Kristelle J. Capistrano, Min Peng, Alejo Efeyan, David M. Sabatini, Ming O. Li. Nutrient mTORC1 signaling underpins regulatory T cell control of immune tolerance. J Exp Med. 2020 Jan 6;217(1):e20190848.
11.Min Peng, Na Yin, Ming O. Li. SZT2 dictates GATOR control of mTORC1 signaling. Nature. 2017 Mar 16;543(7645):433-437.
12.Min Peng#, Na Yin#, Sagar Chhangawala, Ke Xu, Christina S. Leslie, Ming O. Li. Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science, 2016 Oct 28; 354(6311): 481-484. (#equal contribution)
Preview in Science, 2016 Oct 28; 354(6311): 419-420. “Warburg meets epigenetics”.
Preview in Dev Cell, 2016 November 7;39: 286-287. “Metabolic Control of Cellular Differentiation”.
Preview in Cell Metab, 2016 November 8; 24: 651-652. “Metabolic Signaling Drives IFN-g”.
13.Jiangbin Ye, Wilhelm Palm, Min Peng, Bryan King, Tullia Lindsten, Ming O. Li, Constantinos Koumenis, Craig B. Thompson. GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2. Genes Dev. 2015 Nov 15; 29 (22): 2331-6.
14.Min Peng, Na Yin, Ming O. Li. Sestrins Function as Guanine Nucleotide Dissociation Inhibitors for Rag GTPases to Control mTORC1 Signaling. Cell. 2014 Sep 25; 159(1): 122-33.
Highlighted in Nat Rev Mol Cell Biol, 2014; 15: 701, “A RAG dissociation inhibitor”.
15.Weiming Ouyang, Will Liao, Chong T. Luo, Na Yin, Morgan Huse, Myoungjoo V. Kim, Min Peng, Pamela Chan, Qian Ma, Yifan Mo, Dies Meijer, Keji Zhao, Alexander Y. Rudensky, Gurinder Atwal, Michael Q. Zhang, Ming O. Li. Novel Foxo1-dependent transcriptional programs control Treg cell function. Nature. 2012 Nov 22; 491(7425): 554-9
16.Min Peng,Sha Guo,Na Yin, Jing Xue, Lian Shen, Qing Zhao, Wei Zhang. Ectodomain shedding of Fcalpha receptor is mediated by ADAM10 and ADAM17. Immunology, 2010, 130(1): 83-91
17.Min Peng; Na Yin; Wei Zhang. Endocytosis of FcaR is clathrin and dynamin dependent but its cytoplasmic domain is not required. Cell Res, 2009, 20(2): 223-237
18.Na Yin; Min Peng; Yukun Xing; Wei Zhang. Intracellular pools of FcalphaR (CD89) in human neutrophils are localized in tertiary granules and secretory vesicles, and two FcalphaR isoforms are found in tertiary granules. J Leukoc Biol. 2007, 82: 551-558
Complete list of publications: https://orcid.org/0000-0002-5885-0660
